Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

Individualized chemotherapy based on organ selectivity: a retrospective study of vinorelbine and capecitabine for patients with metastatic breast cancer.

Liu XH, Man YN, Cao R, Liu C, Wu XZ.

Curr Med Res Opin. 2014 Jun;30(6):1017-24. doi: 10.1185/03007995.2014.895310. Epub 2014 Mar 10.

PMID:
24528110
2.

Survival differences observed in metastatic breast cancer patients treated with capecitabine when compared with vinorelbine after pretreatment with anthracycline and taxane.

Verma S, Wong NS, Trudeau M, Joy A, Mackey J, Dranitsaris G, Clemons M.

Am J Clin Oncol. 2007 Jun;30(3):297-302.

PMID:
17551309
3.

Sequential therapy with capecitabine followed by vinorelbine/cisplatin in patients with anthracycline/taxane-refractory metastatic breast cancer.

Lin PC, Wang WS, Yang MH, Yen CC, Chao TC, Hsiao LT, Chen PM.

J Chin Med Assoc. 2006 Jul;69(7):304-9.

4.

A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer.

Pallis AG, Boukovinas I, Ardavanis A, Varthalitis I, Malamos N, Georgoulias V, Mavroudis D.

Ann Oncol. 2012 May;23(5):1164-9. doi: 10.1093/annonc/mdr405. Epub 2011 Sep 21.

PMID:
21937705
5.

Final results of an international retrospective observational study in patients with advanced breast cancer treated with oral vinorelbine-based chemotherapy.

Palomo AG, Glogowska I, Sommer H, Malamos N, Kilar E, Vega JM, Torrecillas L, Delozier T, Ettl J, Finek J.

Anticancer Res. 2012 Oct;32(10):4539-45.

PMID:
23060583
6.

Efficacy of S-1 in heavily pretreated patients with metastatic breast cancer: cross-resistance to capecitabine.

Ito Y, Osaki Y, Tokudome N, Sugihara T, Takahashi S, Iwase T, Hatake K.

Breast Cancer. 2009;16(2):126-31. doi: 10.1007/s12282-008-0073-9. Epub 2008 Sep 20.

PMID:
18807123
7.

Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: findings from the EORTC 10001 randomized phase II trial.

Pajk B, Cufer T, Canney P, Ellis P, Cameron D, Blot E, Vermorken J, Coleman R, Marreaud S, Bogaerts J, Basaran G, Piccart M.

Breast. 2008 Apr;17(2):180-5. Epub 2007 Oct 31.

PMID:
17976988
8.

Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational?

Zhang J, Gu SY, Gan Y, Wang ZH, Wang BY, Guo HY, Wang JL, Wang LP, Zhao XM, Hu XC.

Cancer Chemother Pharmacol. 2013 Jan;71(1):103-13. doi: 10.1007/s00280-012-1983-y. Epub 2012 Oct 2.

PMID:
23053266
9.

Capecitabine and vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxane.

Ahn JH, Kim SB, Kim TW, Ahn SH, Kim SM, Park JM, Lee JS, Kang YK, Kim WK.

J Korean Med Sci. 2004 Aug;19(4):547-53.

10.

Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.

Jones A, O'Brien M, Sommer H, Nowara E, Welt A, Pienkowski T, Rolski J, Pham ML, Perraud K, Trillet-Lenoir V.

Cancer Chemother Pharmacol. 2010 Mar;65(4):755-63. doi: 10.1007/s00280-009-1081-y. Epub 2009 Aug 9.

PMID:
19669644
11.

Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes.

Fan Y, Xu B, Yuan P, Wang J, Ma F, Li Q, Zhang P, Li Q, Cai R.

Chemotherapy. 2010;56(4):340-7. doi: 10.1159/000320186. Epub 2010 Aug 18.

PMID:
20720418
12.

Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.

Gilabert M, Bertucci F, Esterni B, Madroszyk A, Tarpin C, Jacquemier J, Extra JM, Viens P, Gonçalves A.

Anticancer Res. 2011 Mar;31(3):1079-86.

PMID:
21498742
13.

Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer.

Welt A, von Minckwitz G, Oberhoff C, Borquez D, Schleucher R, Loibl S, Harstrick A, Kaufmann M, Seeber S, Vanhoefer U.

Ann Oncol. 2005 Jan;16(1):64-9.

PMID:
15598940
14.

Safety and efficacy of oral vinorelbine and capecitabine combination for metastatic breast cancer.

Di Seri M, De Sanctis R, Quadrini S, Adua D, Stumbo L, Del Signore E, Gori B, Grassi P, Basile ML, Longo F.

J Chemother. 2011 Apr;23(2):110-3.

PMID:
21571629
15.

Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane.

Park JS, Jeung HC, Rha SY, Ahn JB, Kang B, Chon HJ, Hong MH, Lim S, Yang WI, Nam CM, Chung HC.

Cancer Chemother Pharmacol. 2014 Oct;74(4):799-808. doi: 10.1007/s00280-014-2551-4. Epub 2014 Aug 9.

PMID:
25107569
16.

Ixabepilone plus capecitabine for Chinese patients with metastatic breast cancer progressing after anthracycline and taxane treatment.

Wang J, Fan Y, Xu B.

Cancer Chemother Pharmacol. 2010 Aug;66(3):597-603. doi: 10.1007/s00280-010-1362-5. Epub 2010 May 21.

PMID:
20490795
17.

An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study.

Wang Z, Lu J, Leaw S, Hong X, Wang J, Shao Z, Hu X.

Cancer Chemother Pharmacol. 2012 Feb;69(2):515-22. doi: 10.1007/s00280-011-1728-3. Epub 2011 Aug 27.

PMID:
21874317
18.

Vinorelbine and infusional 5-fluorouracil in anthracycline and taxane pre-treated metastatic breast cancer.

Stuart NS, McIllmurray MB, Bishop JL, Johnston SR, Price CG, O'Reilly SM, Joffe JK, Neave F, Whipp EC.

Clin Oncol (R Coll Radiol). 2008 Mar;20(2):152-6.

PMID:
18083354
19.

A Phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines.

Orphanos G, Alexopoulos A, Malliou S, Ioannidis G, Ardavanis A, Kandylis C, Stavrakakis J, Rigatos G.

J Cancer Res Clin Oncol. 2010 Jan;136(1):115-21. doi: 10.1007/s00432-009-0642-0.

PMID:
19672628
20.

A three-arm randomized phase II study of oral vinorelbine plus capecitabine versus oral vinorelbine and capecitabine in sequence versus docetaxel plus capecitabine in patients with metastatic breast cancer previously treated with anthracyclines.

Campone M, Dobrovolskaya N, Tjulandin S, Chen SC, Fourie S, Mefti F, Konstantinova M, Lefresne F, Meheust N, Jassem J.

Breast J. 2013 May-Jun;19(3):240-9. doi: 10.1111/tbj.12098. Epub 2013 Mar 26.

PMID:
23528159

Supplemental Content

Support Center